Insights Into Perrigo (PRGO) Q1: Wall Street Projections for Key Metrics

Core Insights - Perrigo (PRGO) is expected to report quarterly earnings of $0.24 per share, reflecting a 46.7% decline year-over-year, with revenues projected at $1.09 billion, a decrease of 7.6% compared to the previous year [1] - Analysts have revised their consensus EPS estimate upward by 0.6% over the past 30 days, indicating a reassessment of projections [1] - The relationship between earnings estimate revisions and short-term stock price performance is highlighted as a significant factor for investor behavior [1] Financial Metrics - Net Sales for Consumer Self-Care Americas (CSCA) are projected to be $653.51 million, down 14.4% from the year-ago quarter [2] - Net Sales for Consumer Self-Care International (CSCI) are expected to reach $438.50 million, reflecting a 4.9% increase year-over-year [2] - Net Sales for CSCA- Oral care are estimated at $78.21 million, indicating a 7.3% decline from the previous year [2] Additional Sales Projections - Net Sales for CSCA- Nutrition are projected at $42.89 million, showing a significant decrease of 69.3% from the prior-year quarter [3] - The consensus estimate for Net Sales in CSCA- Healthy Lifestyle is $75.24 million, representing a 2.5% increase year-over-year [3] - Analysts predict Net Sales for CSCA- Upper Respiratory to be $151.22 million, indicating a 2% decline from the previous year [3] Geographic Revenue Estimates - Geographic Revenue for Europe is expected to be $368.04 million, down 9.6% year-over-year [3] - Geographic Revenue for the U.S. is projected at $681.34 million, reflecting a 9.2% decrease from the year-ago quarter [3] - Revenue from all other countries is estimated at $35.19 million, indicating a substantial increase of 44.2% from the prior-year quarter [3] Proforma/Adjusted Revenue Estimates - Consumer Self-Care International- GP - Proforma/Adjusted (CSCI) is expected to reach $217.16 million, down from $228.20 million reported in the same quarter last year [4] - Consumer Self-Care Americas- GP - Proforma/Adjusted (CSCA) is projected at $194.01 million, compared to $214.70 million reported in the same quarter of the previous year [4] Stock Performance - Over the past month, Perrigo shares have returned +4.4%, contrasting with the Zacks S&P 500 composite's -1.6% change [4] - Currently, PRGO holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the overall market in the near future [4]